This webinar is brought to you by Equifund Technologies, LLC.
This past Thursday we sat down with Kurt Swogger, CEO and co-founder of Biopact CT for an in-depth interview.
If you are a current investor in the company, or a prospective one, it is well worth a watch. You’ll learn about management’s impressive track record, recent positive developments at the company, and its future prospects.
Why retail investors will become a significant force for change over the next five years.
Here’s why this is important for us early-stage investors to know.
Now that we’ve reached an agreement on the debt-ceiling shakedown, let’s talk about the stories you haven’t been hearing: Investor home purchases drop 49%, the
In the pursuit of outsized returns, I’m always looking for a very specific setup: speculative investment opportunities that I think have mispriced risk factors. Why?
By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.
Proprietary devices that could revolutionize spinal surgery and greatly improve success rates, reduce pain, and lower costs.
Over 20 patents have been issued to protect the company's technologies.
Just received FDA clearance for their next-generation KG2 spinal fusion technology.
The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO
Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:
We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.
Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.
If you have not received the email in 5 minutes, please click here to have it resent.
Questions? Our customer service team is always here to help – 1-866-338-3004
